1bp3 › Citations

The X-ray structure of a growth hormone-prolactin receptor complex.

Somers W, Ultsch M, De Vos AM, Kossiakoff AA
Nature 372 478-81 (1994)
Cited: 205 times
EuropePMC logo PMID: 7984244

Abstract

The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation. These activities are initiated by hormone-receptor binding. The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily. This classification is based on sequence similarity in their extracellular domains, notably a highly conserved pentapeptide, the so-called 'WSXWS box', the function of which is controversial. All ligands in class 1 activate their respective receptors by clustering mechanisms. In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap. We present here the crystal structure of the 1:1 complex of hGH bound to the extracellular domain of the hPRLR. Comparisons with the hGH-hGHR complex reveal how hGH can bind to the two distinctly different receptor binding surfaces.

Reviews - 1bp3 mentioned but not cited (1)

  1. Overview of protein structural and functional folds. Sun PD, Foster CE, Boyington JC. Curr Protoc Protein Sci Chapter 17 Unit 17.1 (2004)

Articles - 1bp3 mentioned but not cited (15)

  1. Crisponi syndrome is caused by mutations in the CRLF1 gene and is allelic to cold-induced sweating syndrome type 1. Crisponi L, Crisponi G, Meloni A, Toliat MR, Nurnberg G, Usala G, Uda M, Masala M, Hohne W, Becker C, Marongiu M, Chiappe F, Kleta R, Rauch A, Wollnik B, Strasser F, Reese T, Jakobs C, Kurlemann G, Cao A, Nurnberg P, Rutsch F. Am J Hum Genet 80 971-981 (2007)
  2. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P, Benign Breast Diseases Study Group. Proc Natl Acad Sci U S A 105 14533-14538 (2008)
  3. Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database. Bickerton GR, Higueruelo AP, Blundell TL. BMC Bioinformatics 12 313 (2011)
  4. Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2. Broutin I, Jomain JB, Tallet E, van Agthoven J, Raynal B, Hoos S, Kragelund BB, Kelly PA, Ducruix A, England P, Goffin V. J Biol Chem 285 8422-8433 (2010)
  5. Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration. Nan R, Farabella I, Schumacher FF, Miller A, Gor J, Martin AC, Jones DT, Lengyel I, Perkins SJ. J Mol Biol 408 714-735 (2011)
  6. In silico investigation of pH-dependence of prolactin and human growth hormone binding to human prolactin receptor. Wang L, Witham S, Zhang Z, Li L, Hodsdon ME, Alexov E. Commun Comput Phys 13 207-222 (2013)
  7. Intramolecular disulfide bonds of the prolactin receptor short form are required for its inhibitory action on the function of the long form of the receptor. Xie YL, Hassan SA, Qazi AM, Tsai-Morris CH, Dufau ML. Mol Cell Biol 29 2546-2555 (2009)
  8. Impact of subdomain D1 of the short form S1b of the human prolactin receptor on its inhibitory action on the function of the long form of the receptor induced by prolactin. Kang JH, Hassan SA, Zhao P, Tsai-Morris CH, Dufau ML. Biochim Biophys Acta 1840 2272-2280 (2014)
  9. Combined computational design of a zinc-binding site and a protein-protein interaction: one open zinc coordination site was not a robust hotspot for de novo ubiquitin binding. Der BS, Jha RK, Lewis SM, Thompson PM, Guntas G, Kuhlman B. Proteins 81 1245-1255 (2013)
  10. Predicting Protein-Protein Interaction Sites Using Sequence Descriptors and Site Propensity of Neighboring Amino Acids. Kuo TH, Li KB. Int J Mol Sci 17 E1788 (2016)
  11. Quantitative Assessment of Chirality of Protein Secondary Structures and Phenylalanine Peptide Nanotubes. Sidorova A, Bystrov V, Lutsenko A, Shpigun D, Belova E, Likhachev I. Nanomaterials (Basel) 11 3299 (2021)
  12. Amino acid substitutions in human growth hormone affect secondary structure and receptor binding. Rajkovic A, Kanchugal S, Abdurakhmanov E, Howard R, Wärmländer S, Erwin J, Barrera Saldaña HA, Gräslund A, Danielson H, Flores SC. PLoS One 18 e0282741 (2023)
  13. Architecture of the two metal-binding sites in prolactin. Vang J, Pustovalova Y, Korzhnev DM, Gorbatyuk O, Keeler C, Hodsdon ME, Hoch JC. Biophys J 121 1312-1321 (2022)
  14. Isolation and Characterization of the Arapaima gigas Growth Hormone (ag-GH) cDNA and Three-Dimensional Modeling of This Hormone in Comparison with the Human Hormone (hGH). Lima ER, Freire RP, Suzuki MF, Oliveira JE, Yosidaki VL, Peroni CN, Sevilhano T, Zorzeto M, Torati LS, Soares CRJ, Lima IDM, Kronenberger T, Maltarollo VG, Bartolini P. Biomolecules 13 158 (2023)
  15. research-article Structural modeling of cytokine-receptor-JAK2 signaling complexes using AlphaFold Multimer. Pogozheva ID, Cherepanov S, Park SJ, Raghavan M, Im W, Lomize AL. bioRxiv 2023.06.14.544971 (2023)


Reviews citing this publication (43)

  1. Anatomy of hot spots in protein interfaces. Bogan AA, Thorn KS. J Mol Biol 280 1-9 (1998)
  2. Zinc and brain injury. Choi DW, Koh JY. Annu Rev Neurosci 21 347-375 (1998)
  3. Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. Annu Rev Immunol 20 853-885 (2002)
  4. Interleukin-6: structure-function relationships. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Protein Sci 6 929-955 (1997)
  5. Structure and distribution of modules in extracellular proteins. Bork P, Downing AK, Kieffer B, Campbell ID. Q Rev Biophys 29 119-167 (1996)
  6. Functions of fibroblast growth factors and their receptors. Wilkie AO, Morriss-Kay GM, Jones EY, Heath JK. Curr Biol 5 500-507 (1995)
  7. The type I interferon receptor: structure, function, and evolution of a family business. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uzé G. J Interferon Cytokine Res 19 1069-1098 (1999)
  8. Structure and function of fibronectin modules. Potts JR, Campbell ID. Matrix Biol 15 313-20; discussion 321 (1996)
  9. Cytokine receptor signal transduction and the control of hematopoietic cell development. Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. Annu Rev Cell Dev Biol 12 91-128 (1996)
  10. Prolactin regulation of mammary gland development. Oakes SR, Rogers RL, Naylor MJ, Ormandy CJ. J Mammary Gland Biol Neoplasia 13 13-28 (2008)
  11. FN3: a new protein scaffold reaches the clinic. Bloom L, Calabro V. Drug Discov Today 14 949-955 (2009)
  12. Molecular mechanisms of prolactin and its receptor. Brooks CL. Endocr Rev 33 504-525 (2012)
  13. IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Grötzinger J, Kernebeck T, Kallen KJ, Rose-John S. Biol Chem 380 803-813 (1999)
  14. Prolactin receptor signal transduction. Clevenger CV, Kline JB. Lupus 10 706-718 (2001)
  15. The prolactin/growth hormone receptor family: structure/function relationships. Goffin V, Kelly PA. J Mammary Gland Biol Neoplasia 2 7-17 (1997)
  16. Four-helix bundle growth factors and their receptors: protein-protein interactions. Mott HR, Campbell ID. Curr Opin Struct Biol 5 114-121 (1995)
  17. Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors. Deng L, Mariuzza RA. Semin Immunol 18 159-166 (2006)
  18. Regulation of prolactin receptor levels and activity in breast cancer. Swaminathan G, Varghese B, Fuchs SY. J Mammary Gland Biol Neoplasia 13 81-91 (2008)
  19. Comparison of the intermediate complexes of human growth hormone bound to the human growth hormone and prolactin receptors. Kossiakoff AA, Somers W, Ultsch M, Andow K, Muller YA, De Vos AM. Protein Sci 3 1697-1705 (1994)
  20. Structural basis for recognition of cellular and viral ligands by NK cell receptors. Li Y, Mariuzza RA. Front Immunol 5 123 (2014)
  21. Natural inhibitors of snake venom hemorrhagic metalloproteinases. Perales J, Neves-Ferreira AG, Valente RH, Domont GB. Toxicon 45 1013-1020 (2005)
  22. Trace metals in the brain: allosteric modulators of ligand-gated receptor channels, the case of ATP-gated P2X receptors. Huidobro-Toro JP, Lorca RA, Coddou C. Eur Biophys J 37 301-314 (2008)
  23. Mechanism of ruminant placental lactogen action: molecular and in vivo studies. Gertler A, Djiane J. Mol Genet Metab 75 189-201 (2002)
  24. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL, Fang F. J Mammary Gland Biol Neoplasia 13 147-156 (2008)
  25. Tissue factor structure and function. Butenas S. Scientifica (Cairo) 2012 964862 (2012)
  26. Piecing together the puzzle of pancreatic islet adaptation in pregnancy. Banerjee RR. Ann N Y Acad Sci 1411 120-139 (2018)
  27. Membrane catalysis of peptide-receptor binding. Langelaan DN, Rainey JK. Biochem Cell Biol 88 203-210 (2010)
  28. Molecular recognition events involved in the activation of the growth hormone receptor by growth hormone. Behncken SN, Waters MJ. J Mol Recognit 12 355-362 (1999)
  29. Hemopoietic growth factor receptor abnormalities in leukemia. Alexander WS, Nicola NA. Leuk Res 22 1097-1111 (1998)
  30. Conformational changes in MHC class I molecules. Antibody, T-cell receptor, and NK cell recognition in an HLA-B7 model system. Smith KD, Kurago ZB, Lutz CT. Immunol Res 16 243-259 (1997)
  31. Metal-dependent hormone function: the emerging interdisciplinary field of metalloendocrinology. Stevenson MJ, Uyeda KS, Harder NHO, Heffern MC. Metallomics 11 85-110 (2019)
  32. Classical and novel GH receptor signaling pathways. Frank SJ. Mol Cell Endocrinol 518 110999 (2020)
  33. Role of cyclophilins in somatolactogenic action. Rycyzyn MA, Clevenger CV. Ann N Y Acad Sci 917 514-521 (2000)
  34. Recognition at the cell surface: recent structural insights. Stuart DI, Jones EY. Curr Opin Struct Biol 5 735-743 (1995)
  35. Recombinant analogues of prolactin, growth hormone, and placental lactogen: correlations between physical structure, binding characteristics, and activity. Gertler A. J Mammary Gland Biol Neoplasia 2 69-80 (1997)
  36. Interfacial metal-binding site design. Matthews DJ. Curr Opin Biotechnol 6 419-424 (1995)
  37. Prolactin-dependent modulation of organogenesis in the vertebrate: Recent discoveries in zebrafish. Nguyen N, Stellwag EJ, Zhu Y. Comp Biochem Physiol C Toxicol Pharmacol 148 370-380 (2008)
  38. Staphylococcal enterotoxins A, D, and E. Structure and function, including mechanism of T-cell superantigenicity. Svensson LA, Schad EM, Sundström M, Antonsson P, Kalland T, Dohlsten M. Prep Biochem Biotechnol 27 111-141 (1997)
  39. Tissue factor and biotechnology. Martin DM, Wiiger MT, Prydz H. Thromb Res 90 1-25 (1998)
  40. Interaction of lactogenic hormones with prolactin receptors. Gertler A, Grosclaude J, Djiane J. Ann N Y Acad Sci 839 177-181 (1998)
  41. Putting two and two together: crystal structure of the FGF-receptor complex. Wiesmann C, de Vos AM. Structure 7 R251-5 (1999)
  42. Receptors of the cytokine superfamily: mechanisms of activation and involvement in disease. Woodcock JM, Bagley CJ, Lopez AF. Baillieres Clin Haematol 10 507-524 (1997)
  43. Protein structures in receptor classification. Barnard EA. Ann N Y Acad Sci 812 14-28 (1997)

Articles citing this publication (146)

  1. A hot spot of binding energy in a hormone-receptor interface. Clackson T, Wells JA. Science 267 383-386 (1995)
  2. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Science 283 987-990 (1999)
  3. Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. Walter MR, Windsor WT, Nagabhushan TL, Lundell DJ, Lunn CA, Zauodny PJ, Narula SK. Nature 376 230-235 (1995)
  4. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Fan QR, Long EO, Wiley DC. Nat Immunol 2 452-460 (2001)
  5. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH. J Cell Biol 159 373-382 (2002)
  6. Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. Clackson T, Ultsch MH, Wells JA, de Vos AM. J Mol Biol 277 1111-1128 (1998)
  7. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. Somers W, Stahl M, Seehra JS. EMBO J 16 989-997 (1997)
  8. Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Zdanov A, Schalk-Hihi C, Gustchina A, Tsang M, Weatherbee J, Wlodawer A. Structure 3 591-601 (1995)
  9. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Muller YA, Christinger HW, Keyt BA, de Vos AM. Structure 5 1325-1338 (1997)
  10. Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors. Fan QR, Mosyak L, Winter CC, Wagtmann N, Long EO, Wiley DC. Nature 389 96-100 (1997)
  11. Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12. Yoon C, Johnston SC, Tang J, Stahl M, Tobin JF, Somers WS. EMBO J 19 3530-3541 (2000)
  12. Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2). Chapman TL, Heikema AP, West AP, Bjorkman PJ. Immunity 13 727-736 (2000)
  13. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Skiniotis G, Boulanger MJ, Garcia KC, Walz T. Nat Struct Mol Biol 12 545-551 (2005)
  14. Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Snyder GA, Brooks AG, Sun PD. Proc Natl Acad Sci U S A 96 3864-3869 (1999)
  15. Cryo-EM Structure of Caspase-8 Tandem DED Filament Reveals Assembly and Regulation Mechanisms of the Death-Inducing Signaling Complex. Fu TM, Li Y, Lu A, Li Z, Vajjhala PR, Cruz AC, Srivastava DB, DiMaio F, Penczek PA, Siegel RM, Stacey KJ, Egelman EH, Wu H. Mol Cell 64 236-250 (2016)
  16. Design of potent selective zinc-mediated serine protease inhibitors. Katz BA, Clark JM, Finer-Moore JS, Jenkins TE, Johnson CR, Ross MJ, Luong C, Moore WR, Stroud RM. Nature 391 608-612 (1998)
  17. Crystal structure of a cytokine-binding region of gp130. Bravo J, Staunton D, Heath JK, Jones EY. EMBO J 17 1665-1674 (1998)
  18. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Gadd SL, Clevenger CV. Mol Endocrinol 20 2734-2746 (2006)
  19. Crystal structure of the human p58 killer cell inhibitory receptor (KIR2DL3) specific for HLA-Cw3-related MHC class I. Maenaka K, Juji T, Stuart DI, Jones EY. Structure 7 391-398 (1999)
  20. Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, Mann DA, Woltring DM, Walker I, Ollis DL, Young IG. Cell 104 291-300 (2001)
  21. C. elegans DPY-19 is a C-mannosyltransferase glycosylating thrombospondin repeats. Buettner FF, Ashikov A, Tiemann B, Lehle L, Bakker H. Mol Cell 50 295-302 (2013)
  22. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. McFarland BJ, Strong RK. Immunity 19 803-812 (2003)
  23. Molecular assembly of the period-cryptochrome circadian transcriptional repressor complex. Nangle SN, Rosensweig C, Koike N, Tei H, Takahashi JS, Green CB, Zheng N. Elife 3 e03674 (2014)
  24. Characterization of the interaction between interleukin-13 and interleukin-13 receptors. Arima K, Sato K, Tanaka G, Kanaji S, Terada T, Honjo E, Kuroki R, Matsuo Y, Izuhara K. J Biol Chem 280 24915-24922 (2005)
  25. Crystal structure of human interleukin-10 at 1.6 A resolution and a model of a complex with its soluble receptor. Zdanov A, Schalk-Hihi C, Wlodawer A. Protein Sci 5 1955-1962 (1996)
  26. An interleukin-2 receptor gamma chain mutation with normal thymus morphology. Sharfe N, Shahar M, Roifman CM. J Clin Invest 100 3036-3043 (1997)
  27. Metal-catalyzed oxidation of histidine in human growth hormone. Mechanism, isotope effects, and inhibition by a mild denaturing alcohol. Zhao F, Ghezzo-Schöneich E, Aced GI, Hong J, Milby T, Schöneich C. J Biol Chem 272 9019-9029 (1997)
  28. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Grötzinger J, Kurapkat G, Wollmer A, Kalai M, Rose-John S. Proteins 27 96-109 (1997)
  29. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex. Thiel DJ, le Du MH, Walter RL, D'Arcy A, Chène C, Fountoulakis M, Garotta G, Winkler FK, Ealick SE. Structure 8 927-936 (2000)
  30. Solution structure of human prolactin. Teilum K, Hoch JC, Goffin V, Kinet S, Martial JA, Kragelund BB. J Mol Biol 351 810-823 (2005)
  31. The Cys(3)-His(1) motif of the respiratory syncytial virus M2-1 protein is essential for protein function. Hardy RW, Wertz GW. J Virol 74 5880-5885 (2000)
  32. The N-terminal globular domain of Eph receptors is sufficient for ligand binding and receptor signaling. Labrador JP, Brambilla R, Klein R. EMBO J 16 3889-3897 (1997)
  33. Evolution of receptors for growth hormone and somatolactin in fish and land vertebrates: lessons from the lungfish and sturgeon orthologues. Fukamachi S, Meyer A. J Mol Evol 65 359-372 (2007)
  34. Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins. Ross GM, Shamovsky IL, Lawrance G, Solc M, Dostaler SM, Jimmo SL, Weaver DF, Riopelle RJ. Nat Med 3 872-878 (1997)
  35. Episodic evolution of growth hormone in primates and emergence of the species specificity of human growth hormone receptor. Liu JC, Makova KD, Adkins RM, Gibson S, Li WH. Mol Biol Evol 18 945-953 (2001)
  36. Crystal structure of LIR-2 (ILT4) at 1.8 A: differences from LIR-1 (ILT2) in regions implicated in the binding of the Human Cytomegalovirus class I MHC homolog UL18. Willcox BE, Thomas LM, Chapman TL, Heikema AP, West AP, Bjorkman PJ. BMC Struct Biol 2 6 (2002)
  37. Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody. Beyer BM, Ingram R, Ramanathan L, Reichert P, Le HV, Madison V, Orth P. J Mol Biol 382 942-955 (2008)
  38. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Xu J, Zhang Y, Berry PA, Jiang J, Lobie PE, Langenheim JF, Chen WY, Frank SJ. Mol Endocrinol 25 597-610 (2011)
  39. Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization. Bernat B, Pal G, Sun M, Kossiakoff AA. Proc Natl Acad Sci U S A 100 952-957 (2003)
  40. Changes in mRNA expression of grouper (Epinephelus coioides) growth hormone and insulin-like growth factor I in response to nutritional status. Pedroso FL, de Jesus-Ayson EG, Cortado HH, Hyodo S, Ayson FG. Gen Comp Endocrinol 145 237-246 (2006)
  41. Subcloning, expression, purification, and characterization of recombinant human leptin-binding domain. Sandowski Y, Raver N, Gussakovsky EE, Shochat S, Dym O, Livnah O, Rubinstein M, Krishna R, Gertler A. J Biol Chem 277 46304-46309 (2002)
  42. Mapping leptin-interacting sites in recombinant leptin-binding domain (LBD) subcloned from chicken leptin receptor. Niv-Spector L, Raver N, Friedman-Einat M, Grosclaude J, Gussakovsky EE, Livnah O, Gertler A. Biochem J 390 475-484 (2005)
  43. The tertiary structure and backbone dynamics of human prolactin. Keeler C, Dannies PS, Hodsdon ME. J Mol Biol 328 1105-1121 (2003)
  44. The functional binding epitope of a high affinity variant of human growth hormone mapped by shotgun alanine-scanning mutagenesis: insights into the mechanisms responsible for improved affinity. Pal G, Kossiakoff AA, Sidhu SS. J Mol Biol 332 195-204 (2003)
  45. Amyloid formation of growth hormone in presence of zinc: Relevance to its storage in secretory granules. Jacob RS, Das S, Ghosh S, Anoop A, Jha NN, Khan T, Singru P, Kumar A, Maji SK. Sci Rep 6 23370 (2016)
  46. Solution structure of the inner DysF domain of myoferlin and implications for limb girdle muscular dystrophy type 2b. Patel P, Harris R, Geddes SM, Strehle EM, Watson JD, Bashir R, Bushby K, Driscoll PC, Keep NH. J Mol Biol 379 981-990 (2008)
  47. Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site. Deng Q, Zhai JW, Michel ML, Zhang J, Qin J, Kong YY, Zhang XX, Budkowska A, Tiollais P, Wang Y, Xie YH. J Virol 81 4244-4254 (2007)
  48. Modeled structure of the 75-kDa neurotrophin receptor. Chapman BS, Kuntz ID. Protein Sci 4 1696-1707 (1995)
  49. The structure and activity of a monomeric interferon-gamma:alpha-chain receptor signaling complex. Randal M, Kossiakoff AA. Structure 9 155-163 (2001)
  50. Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo. Gatot JS, Callebaut I, Van Lint C, Demonté D, Kerkhofs P, Portetelle D, Burny A, Willems L, Kettmann R. J Virol 76 7956-7967 (2002)
  51. Crystal structure of the human monocyte-activating receptor, "Group 2" leukocyte Ig-like receptor A5 (LILRA5/LIR9/ILT11). Shiroishi M, Kajikawa M, Kuroki K, Ose T, Kohda D, Maenaka K. J Biol Chem 281 19536-19544 (2006)
  52. Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization. Walsh ST, Jevitts LM, Sylvester JE, Kossiakoff AA. Protein Sci 12 1960-1970 (2003)
  53. Secretion of authentic 20-kDa human growth hormone (20K hGH) in Escherichia coli and properties of the purified product. Uchida H, Naito N, Asada N, Wada M, Ikeda M, Kobayashi H, Asanagi M, Mori K, Fujita Y, Konda K, Kusuhara N, Kamioka T, Nakashima K, Honjo M. J Biotechnol 55 101-112 (1997)
  54. Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone. van Agthoven J, Zhang C, Tallet E, Raynal B, Hoos S, Baron B, England P, Goffin V, Broutin I. J Mol Biol 404 112-126 (2010)
  55. Synthesis and screening of a cyclic peptide library: discovery of small-molecule ligands against human prolactin receptor. Liu T, Joo SH, Voorhees JL, Brooks CL, Pei D. Bioorg Med Chem 17 1026-1033 (2009)
  56. The high- and low-affinity receptor binding sites of growth hormone are allosterically coupled. Walsh ST, Sylvester JE, Kossiakoff AA. Proc Natl Acad Sci U S A 101 17078-17083 (2004)
  57. A growth hormone agonist produced by targeted mutagenesis at binding site 1. Evidence that site 1 regulates bioactivity. Rowlinson SW, Barnard R, Bastiras S, Robins AJ, Brinkworth R, Waters MJ. J Biol Chem 270 16833-16839 (1995)
  58. Definition of a composite binding site for gp130 in human interleukin-6. Ciapponi L, Graziani R, Paonessa G, Lahm A, Ciliberto G, Savino R. J Biol Chem 270 31249-31254 (1995)
  59. Neutralizing epitopes on the extracellular interferon gamma receptor (IFNgammaR) alpha-chain characterized by homolog scanning mutagenesis and X-ray crystal structure of the A6 fab-IFNgammaR1-108 complex. Sogabe S, Stuart F, Henke C, Bridges A, Williams G, Birch A, Winkler FK, Robinson JA. J Mol Biol 273 882-897 (1997)
  60. Solution structure of an extracellular domain containing the WSxWS motif of the granulocyte colony-stimulating factor receptor and its interaction with ligand. Yamasaki K, Naito S, Anaguchi H, Ohkubo T, Ota Y. Nat Struct Biol 4 498-504 (1997)
  61. Structure of a phage display-derived variant of human growth hormone complexed to two copies of the extracellular domain of its receptor: evidence for strong structural coupling between receptor binding sites. Schiffer C, Ultsch M, Walsh S, Somers W, de Vos AM, Kossiakoff A. J Mol Biol 316 277-289 (2002)
  62. The role of prolactin receptor in GH signaling in breast cancer cells. Xu J, Sun D, Jiang J, Deng L, Zhang Y, Yu H, Bahl D, Langenheim JF, Chen WY, Fuchs SY, Frank SJ. Mol Endocrinol 27 266-279 (2013)
  63. A third fibronectin type III domain in the extracellular region of the insulin receptor family. Marino-Buslje C, Mizuguchi K, Siddle K, Blundell TL. FEBS Lett 441 331-336 (1998)
  64. Participation of two Ser-Ser-Phe-Tyr repeats in interleukin-6 (IL-6)-binding sites of the human IL-6 receptor. Kalai M, Montero-Julian FA, Grötzinger J, Wollmer A, Morelle D, Brochier J, Rose-John S, Heinrich PC, Brailly H, Content J. Eur J Biochem 238 714-723 (1996)
  65. Preparation and characterization of recombinant prolactin receptor extracellular domain from rat. Sandowski Y, Nagano M, Bignon C, Djiane J, Kelly PA, Gertler A. Mol Cell Endocrinol 115 1-11 (1995)
  66. Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases. Katz BA, Luong C. J Mol Biol 292 669-684 (1999)
  67. Convergent Evolution of Slick Coat in Cattle through Truncation Mutations in the Prolactin Receptor. Porto-Neto LR, Bickhart DM, Landaeta-Hernandez AJ, Utsunomiya YT, Pagan M, Jimenez E, Hansen PJ, Dikmen S, Schroeder SG, Kim ES, Sun J, Crespo E, Amati N, Cole JB, Null DJ, Garcia JF, Reverter A, Barendse W, Sonstegard TS. Front Genet 9 57 (2018)
  68. Identification of a ligand-binding site on the granulocyte colony-stimulating factor receptor by molecular modeling and mutagenesis. Layton JE, Iaria J, Smith DK, Treutlein HR. J Biol Chem 272 29735-29741 (1997)
  69. The solution structure of the cytokine-binding domain of the common beta-chain of the receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3 and interleukin-5. Mulhern TD, Lopez AF, D'Andrea RJ, Gaunt C, Vandeleur L, Vadas MA, Booker GW, Bagley CJ. J Mol Biol 297 989-1001 (2000)
  70. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. Langenheim JF, Tan D, Walker AM, Chen WY. Mol Endocrinol 20 661-674 (2006)
  71. Engineering synthetic antibody binders for allosteric inhibition of prolactin receptor signaling. Rizk SS, Kouadio JL, Szymborska A, Duguid EM, Mukherjee S, Zheng J, Clevenger CV, Kossiakoff AA. Cell Commun Signal 13 1 (2015)
  72. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex. Moritz RL, Ward LD, Tu GF, Fabri LJ, Ji H, Yasukawa K, Simpson RJ. Growth Factors 16 265-278 (1999)
  73. Crystal structure and site 1 binding energetics of human placental lactogen. Walsh ST, Kossiakoff AA. J Mol Biol 358 773-784 (2006)
  74. Functional promiscuity of squirrel monkey growth hormone receptor toward both primate and nonprimate growth hormones. Yi S, Bernat B, Pál G, Kossiakoff A, Li WH. Mol Biol Evol 19 1083-1092 (2002)
  75. Molecular modeling of the GM-CSF and IL-3 receptor complexes. Lyne PD, Bamborough P, Duncan D, Richards WG. Protein Sci 4 2223-2233 (1995)
  76. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor. Tsunekawa B, Wada M, Ikeda M, Uchida H, Naito N, Honjo M. Endocrinology 140 3909-3918 (1999)
  77. Critical relationship between glycosylation of recombinant lutropin receptor ectodomain and its secretion from baculovirus-infected insect cells. Pajot-Augy E, Bozon V, Remy JJ, Couture L, Salesse R. Eur J Biochem 260 635-648 (1999)
  78. The Ig-like domain of human GM-CSF receptor alpha plays a critical role in cytokine binding and receptor activation. Mirza S, Walker A, Chen J, Murphy JM, Young IG. Biochem J 426 307-317 (2010)
  79. pH-induced transition and Zn2+-binding properties of bovine prolactin. Permyakov EA, Veprintsev DB, Deikus GY, Permyakov SE, Kalinichenko LP, Grishchenko VM, Brooks CL. FEBS Lett 405 273-276 (1997)
  80. Growth hormone potentiates 17β-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling. Felice DL, El-Shennawy L, Zhao S, Lantvit DL, Shen Q, Unterman TG, Swanson SM, Frasor J. Endocrinology 154 3219-3227 (2013)
  81. Molecular cloning of growth hormone-encoding cDNA of an Indian major carp, Labeo rohita, and its expression in Escherichia coli and zebrafish. Thayanithy V, Anathy V, Pandian TJ, Gong GZ, Mathavan S. Gen Comp Endocrinol 125 236-247 (2002)
  82. Recombinant prolactin receptor extracellular domain of rainbow trout (Oncorhynchus mykiss): subcloning, preparation, and characterization. Sandowski Y, Cohen Y, Le Rouzic P, Bignon C, Rentier-Delrue F, Djiane J, Prunet P, Gertler A. Gen Comp Endocrinol 118 302-309 (2000)
  83. The signal transducer gp130: solution structure of the carboxy-terminal domain of the cytokine receptor homology region. Kernebeck T, Pflanz S, Müller-Newen G, Kurapkat G, Scheek RM, Dijkstra K, Heinrich PC, Wollmer A, Grzesiek S, Grötzinger J. Protein Sci 8 5-12 (1999)
  84. An immobilised peptide array identifies antibodies to a discontinuous epitope in the extracellular domain of the bovine growth hormone receptor. Beattie J, Shand JH, Flint DJ. Eur J Biochem 239 479-486 (1996)
  85. Analysis of site-specific histidine protonation in human prolactin. Tettamanzi MC, Keeler C, Meshack S, Hodsdon ME. Biochemistry 47 8638-8647 (2008)
  86. Computational analysis of ligand binding dynamics at the intermolecular hot spots with the aid of simulated tempering and binding free energy calculations. Verkhivker GM. J Mol Graph Model 22 335-348 (2004)
  87. Principal determinants leading to transition state formation of a protein-protein complex, orientation trumps side-chain interactions. Horn JR, Sosnick TR, Kossiakoff AA. Proc Natl Acad Sci U S A 106 2559-2564 (2009)
  88. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment. Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH, Utama FE, Tanaka T, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Rui H. Breast Cancer Res 15 R73 (2013)
  89. Expression, crystallization and derivatization of the complete extracellular domain of the beta(c) subunit of the human IL-5, IL-3 and GM-CSF receptors. Gustin SE, Church AP, Ford SC, Mann DA, Carr PD, Ollis DL, Young IG. Eur J Biochem 268 2905-2911 (2001)
  90. O-Glycosylated 24 kDa human growth hormone has a mucin-like biantennary disialylated tetrasaccharide attached at Thr-60. Bustamante JJ, Gonzalez L, Carroll CA, Weintraub ST, Aguilar RM, Muñoz J, Martinez AO, Haro LS. Proteomics 9 3474-3488 (2009)
  91. Direct evidence that lactogenic hormones induce homodimerization of membrane-anchored prolactin receptor in intact Nb2-11C rat lymphoma cells. Sakal E, Elberg G, Gertler A. FEBS Lett 410 289-292 (1997)
  92. Gene conversions in the growth hormone gene family of primates: stronger homogenizing effects in the Hominidae lineage. Petronella N, Drouin G. Genomics 98 173-181 (2011)
  93. Homodimerization of IL-2 receptor beta chain is necessary and sufficient to activate Jak2 and downstream signaling pathways. Ferrag F, Pezet A, Chiarenza A, Buteau H, Nelson BH, Goffin V, Kelly PA. FEBS Lett 421 32-36 (1998)
  94. Obligate ordered binding of human lactogenic cytokines. Voorhees JL, Brooks CL. J Biol Chem 285 20022-20030 (2010)
  95. Subdomain 2, Not the Transmembrane Domain, Determines the Dimerization Partner of Growth Hormone Receptor and Prolactin Receptor. Liu Y, Jiang J, Lepik B, Zhang Y, Zinn KR, Frank SJ. Endocrinology 158 3235-3248 (2017)
  96. Growth hormone and two forms of insulin-like growth factors I in the giant grouper (Epinephelus lanceolatus): molecular cloning and characterization of tissue distribution. Dong H, Zeng L, Duan D, Zhang H, Wang Y, Li W, Lin H. Fish Physiol Biochem 36 201-212 (2010)
  97. Higher order iminodiacetic acid libraries for probing protein-protein interactions. Boger DL, Ducray P, Chai W, Jiang W, Goldberg J. Bioorg Med Chem Lett 8 2339-2344 (1998)
  98. Comment Protein-protein interactions. Postmodern complexes. Bazan JF. Nature 376 217-218 (1995)
  99. Seasonal environmental changes modulate the prolactin receptor expression in an eurythermal fish. San Martín R, Cáceres P, Azócar R, Alvarez M, Molina A, Vera MI, Krauskopf M. J Cell Biochem 92 42-52 (2004)
  100. Detection and characterization of an ovine placental lactogen stable intermediate in the urea-induced unfolding process. Cymes GD, Grosman C, Delfino JM, Wolfenstein-Todel C. Protein Sci 5 2074-2079 (1996)
  101. Diabetogenic activity of 20 kDa human growth hormone (20K-hGH) and 22K-hGH in rats. Takahashi S, Shiga Y, Satozawa N, Hayakawa M. Growth Horm IGF Res 11 110-116 (2001)
  102. Human growth hormone fragment (hGH44-91) produces insulin resistance and hyperinsulinemia but is less potent than 22 kDa hGH in the rat. Hettiarachchi M, Watkinson A, Leung KC, Sinha YN, Ho KK, Kraegen EW. Endocrine 6 47-52 (1997)
  103. Human growth hormone site 2 lactogenic activity requires a distant tyrosine164. Duda KM, Brooks CL. FEBS Lett 449 120-124 (1999)
  104. Selective modification at the N-terminal region of human growth hormone that shows antagonistic activity. Tchelet A, Vogel T, Helman D, Guy R, Neospouolus C, Goffin V, Djiane J, Gertler A. Mol Cell Endocrinol 130 141-152 (1997)
  105. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor. Langenheim JF, Chen WY. J Recept Signal Transduct Res 29 107-112 (2009)
  106. Functional relationship of serine 90 phosphorylation and the surrounding putative salt bridge in bovine prolactin. Schenck EJ, Canfield JM, Brooks CL. Mol Cell Endocrinol 204 117-125 (2003)
  107. GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers. Liu Y, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ. Mol Endocrinol 30 504-517 (2016)
  108. LIF receptor-gp130 interaction investigated by homology modeling: implications for LIF binding. Smith DK, Treutlein HR. Protein Sci 7 886-896 (1998)
  109. The signal transducer gp130--bacterial expression, refolding and properties of the carboxy-terminal domain of the cytokine-binding module. Müller-Newen G, Pflanz S, Hassiepen U, Stahl J, Wollmer A, Heinrich PC, Grötzinger J. Eur J Biochem 247 425-431 (1997)
  110. Theoretical investigation of IL-6 multiprotein receptor assembly. Menziani MC, Fanelli F, De Benedetti PG. Proteins 29 528-544 (1997)
  111. Zinc binding to human lactogenic hormones and the human prolactin receptor. Voorhees JL, Rao GV, Gordon TJ, Brooks CL. FEBS Lett 585 1783-1788 (2011)
  112. A partial model of the erythropoietin receptor complex. Caravella JA, Lyne PD, Richards WG. Proteins 24 394-401 (1996)
  113. Biphasic modulation of ryanodine binding to sarcoplasmic reticulum vesicles of skeletal muscle by Zn2+ ions. Xia RH, Cheng XY, Wang H, Chen KY, Wei QQ, Zhang XH, Zhu PH. Biochem J 345 Pt 2 279-286 (2000)
  114. Divergent genes encoding the putative receptors for growth hormone and prolactin in sea lamprey display distinct patterns of expression. Gong N, Ferreira-Martins D, McCormick SD, Sheridan MA. Sci Rep 10 1674 (2020)
  115. Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R). Zhang Y, Gc S, Patel SB, Liu Y, Paterson AJ, Kappes JC, Jiang J, Frank SJ. Mol Cell Endocrinol 492 110445 (2019)
  116. Identification of novel sites in the ovine growth hormone receptor involved in binding hormone and conferring species specificity. Allan GJ, Shand JH, Beattie J, Flint DJ. Eur J Biochem 261 555-562 (1999)
  117. Crystal structure and interaction studies of the human FBxo3 ApaG domain. Krzysiak TC, Chen BB, Lear T, Mallampalli RK, Gronenborn AM. FEBS J 283 2091-2101 (2016)
  118. Macromolecular docking of a three-body system: the recognition of human growth hormone by its receptor. Hendrix DK, Klein TE, Kuntz ID. Protein Sci 8 1010-1022 (1999)
  119. Mink growth hormone structural-functional relationships: effects of renaturing and storage conditions. Borromeo V, Sereikaite J, Bumelis VA, Secchi C, Scirè A, Ausili A, D'Auria S, Tanfani F. Protein J 27 170-180 (2008)
  120. Ovine placental lactogen and human growth hormone bind to different regions of the same receptors. Longhi SA, Wolfenstein-Todel C, Gómez KA, Miranda ME, Retegui LA. Growth Horm IGF Res 9 157-164 (1999)
  121. Relative localization of the prolactin receptor binding sites for lactogenic hormones. Longhi SA, Blank VC, Roguin LP, Cristodero M, Retegui LA. Growth Horm IGF Res 11 324-328 (2001)
  122. Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function. Lau SY, Siau JW, Sobota RM, Wang CI, Zhong P, Lane DP, Ghadessy FJ. Protein Eng Des Sel 31 301-312 (2018)
  123. 22- and 20 kDa-human growth hormones bind to different sites within certain cellular receptors. Longhi SA, Cortés MM, Retegui LA. Growth Horm IGF Res 13 353-360 (2003)
  124. A protein engineering approach differentiates the functional importance of carbohydrate moieties of interleukin-5 receptor α. Ishino T, Economou NJ, McFadden K, Zaks-Zilberman M, Jost M, Baxter S, Contarino MR, Harrington AE, Loll PJ, Pasut G, Lievens S, Tavernier J, Chaiken I. Biochemistry 50 7546-7556 (2011)
  125. Differential tissue response to growth hormone in mice. Berry R, McGinnis GR, Banerjee RR, Young ME, Frank SJ. FEBS Open Bio 8 1146-1154 (2018)
  126. Effects of rGH and G118RrGH on the induction of CYP2C12 and IGF-I in primary rat hepatocytes. Helander H, Clark RG, Mode A. Growth Horm IGF Res 13 287-294 (2003)
  127. Homology modeling of rabbit prolactin hormone complexed with its receptor. Halaby D, Thoreau E, Djiane J, Mornon JP. Proteins 27 459-468 (1997)
  128. Pressuromodulation at the cell membrane as the basis for small molecule hormone and peptide regulation of cellular and nuclear function. Sarin H. J Transl Med 13 372 (2015)
  129. Recombinant extracellular domain of rabbit growth hormone receptor and biological activity of somatogenic hormones. Sakal E, Chapnik-Cohen N, Belair L, Djiane J, Gertler A. Prep Biochem Biotechnol 30 107-123 (2000)
  130. Structure and function of a new class of human prolactin antagonists. DePalatis L, Almgren CM, Patmastan J, Troyer M, Woodrich T, Brooks CL. Protein Expr Purif 66 121-130 (2009)
  131. A novel peptide antagonist of the human growth hormone receptor. Basu R, Nahar K, Kulkarni P, Kerekes O, Sattler M, Hall Z, Neggers S, Holub JM, Kopchick JJ. J Biol Chem 296 100588 (2021)
  132. Cloning and characterization of Pangasianodon hypophthalmus growth hormone gene and its heterologous expression. Sekar M, Singh SD, Gupta S. Appl Biochem Biotechnol 173 1446-1468 (2014)
  133. Discovery of conventional prolactin from the holocephalan elephant fish, Callorhinchus milii. Yamaguchi Y, Takagi W, Kuraku S, Moriyama S, Bell JD, Seale AP, Lerner DT, Grau EG, Hyodo S. Gen Comp Endocrinol 224 216-227 (2015)
  134. Identification, synthesis and properties of a consensus peptide recognized by a monoclonal antibody directed to various type I cytokine receptors. Belloc CG, Longhi SA, Peña C, Blank VA, Miranda ME, Retegui LA. Life Sci 81 553-559 (2007)
  135. Molecular cloning of growth hormone encoding cDNA of Indian major carps by a modified rapid amplification of cDNA ends strategy. Venugopal T, Mathavan S, Pandian TJ. J Biosci 27 261-272 (2002)
  136. Comment Protein-protein interaction. Complex flexibility. Jurnak F. Nature 372 409-410 (1994)
  137. Identification of regions within the third FnIII-like domain of the IL-5Ralpha involved in IL-5 interaction. Czabotar PE, Holland J, Sanderson CJ. Cytokine 12 867-873 (2000)
  138. Resonance assignments, secondary structure and topology of leukaemia inhibitory factor in solution. Hinds MG, Maurer T, Zhang JG, Nicola NA, Norton RS. J Biomol NMR 9 113-126 (1997)
  139. Synthetic peptides as putative therapeutic agents in transplantation medicine: application of PEPSCAN to the identification of functional sequences in the extracellular domain of the interleukin-2 receptor beta chain (IL-2Rbeta). Dionyssopoulou H, Mouzaki A, Slootstra J, Puijk W, Meloen R, Cordopatis P, Sotiropoulou G. J Immunol Methods 241 83-95 (2000)
  140. The role of interchain heterodisulfide formation in activation of the human common beta and mouse betaIL-3 receptors. Mirza S, Chen J, Murphy JM, Young IG. J Biol Chem 285 24759-24768 (2010)
  141. A two-step selection approach for the identification of ligand-binding determinants in cytokine receptors. Friedrich K, Wietek S, Lischke A, Wellbrock C, Kreitman RJ, Pastan I, Sebald W. Anal Biochem 268 179-186 (1999)
  142. Ovine placental lactogen and ovine prolactin: partial proteolysis and conformational stability. Fernández ML, Cymes GD, Curto LM, Wolfenstein-Todel C. Int J Biochem Cell Biol 32 597-608 (2000)
  143. Peptide insertions in domain 4 of hbeta(c), the shared signalling receptor subunit for GM-CSF, IL3 and IL5, induce ligand-independent activation. Jones KL, Bagley CJ, Butcher C, Barry SC, Vadas MA, D'Andrea RJ. Cytokine 14 303-315 (2001)
  144. Purification and functional characterization of a protein: Bombyx mori human growth hormone like protein in silkworm pupa. Chen J, Shu T, Lv Z, Nie Z, Chen J, Chen H, Yu W, Gai Q, Zhang Y. PLoS One 9 e114351 (2014)
  145. Structure and function of a dual antagonist of the human growth hormone and prolactin receptors with site-specific PEG conjugates. Basu R, Brody R, Sandbhor U, Kulkarni P, Davis E, Swegan D, Caggiano LJ, Brenya E, Neggers S, Kopchick JJ. J Biol Chem 299 105030 (2023)
  146. Template-based docking of a prolactin receptor proline-rich motif octapeptide to FKBP12: implications for cytokine receptor signaling. Soman KV, Hanks BA, Tien H, Chari MV, O'Neal KD, Morrisett JD. Protein Sci 6 999-1008 (1997)


Quick links